Malignant Bone Marrow Neoplasm

In this phase III randomized, double-blind placebo-controlled trial, 717 patients with FLT3 mutations (tested for ITD or 835 or 836) underwent randomization 1:1 such that 360 were assigned to the mido… (full text at CIViC)

PMID 28644114 · Stone et al., 2017 · Open in CIViC

A Phase III Randomized, Double-Blind study of chemotherapy + Midostaurin or Placebo in newly diagnosed patients < 60 Years of age with FLT3 mutated Acute Myeloid Leukemia (AML). Overall survival was s… (full text at CIViC)

PMID 28644114 · Stone et al., 2017 · Open in CIViC

Murine pro-B lymphocyte lines Ba/F3 cells with FLT3-ITD were exposed to sorafenib with increasing low doses (i.e., 1-5 nmol/L) of sorafenib for up to 3 months, and further exposed for an additional 3 … (full text at CIViC)

PMID 24619500 · Zhang et al., 2014 · Open in CIViC

Acute myeloid leukemia (AML) with an FLT3 internal tandem duplication (FLT3-ITD) mutation is an aggressive hematologic malignancy with a grave prognosis. Targeted deep sequencing was performed on FLT3… (full text at CIViC)

PMID 26438511 · Garg et al., 2015 · Open in CIViC

By assessing cell viability using MTS assay, FF-10101 showed growth inhibitory effects on FLT3-ITD with Y842C mutation expressing 32D cells(Figure 3A). Consistently, FF-10101 potently inhibited FLT3 p… (full text at CIViC)

PMID 29187377 · Yamaura et al., 2018 · Open in CIViC

Proliferation of Ba/F3 cells with FLT3 double mutations was studied for the activity of ponatinib and sorafenib. Compared to control cells with native FLT3-ITD mutant (IC50: 3.0nM), cells with double … (full text at CIViC)

PMID 23430109 · Smith et al., 2013 · Open in CIViC

From 109 unselected AML patients, one was identified to harbor a FLT3 K663Q mutation in the TK1 domain [outside the juxtamembrane (JM) domain and the activation loop (AL)], homologous to the KIT K642E… (full text at CIViC)

PMID 16990784 · Schittenhelm et al., 2006 · Open in CIViC

Mutations were identified by in vitro saturation mutagenesis on the background of FLT3-ITD or FLT3-ITD/F691L. Proliferation and biochemical studies showed that the FLT3-ITD M664I (IC50 =0.61μM) and FL… (full text at CIViC)

PMID 25847190 · Smith et al., 2015 · Open in CIViC

FLT3 M737I variant was found in patient at diagnosis but absent in the remission sample. BaF3 cells was transformed to express M737I and these cells were unable to grow in the absence of IL-3 similar … (full text at CIViC)

PMID 18068628 · Fröhling et al., 2007 · Open in CIViC

In this cohort, 431 patients (537 specimens underwent targeted NGS, 68 patients underwent more than one sequencing reaction) with an AML diagnosis (new and r/r) were analyzed to identify and character… (full text at CIViC)

PMID 30181385 · Schwartz et al., 2019 · Open in CIViC

FLT3 mutations did not alter overall survival or remission duration in younger (16-60), cytogenetically normal AML patients with CEBPA mutations. 10/36 patients with CEBPA mutations also had FLT3 muta… (full text at CIViC)

PMID 14726504 · Fröhling et al., 2004 · Open in CIViC

In a cohort of 84 de novo AML patients with a CBFB/MYH11 rearrangement and in 36 patients with a RUNX1/RUNX1T1 rearrangement, the FLT3 N676K mutation was identified in 5 and 1 patients, respectively (… (full text at CIViC)

PMID 23878140 · Opatz et al., 2013 · Open in CIViC

This study identified genetic driver mutations by sequencing 111 genes and cytogenetic studies in 1540 samples across three different clinical trials. Table S5 shows all mutations identified in the sa… (full text at CIViC)

PMID 27276561 · Papaemmanuil et al., 2016 · Open in CIViC

In 65 hematologic cancer patient samples (53 AML, 9 ALL, and 3 MDS) partially enriched for lacking FLT3 ITD mutations, resequencing of 21/24 FLT3 exons was performed. In 2 patients with AML, the novel… (full text at CIViC)

PMID 15178581 · Jiang et al., 2004 · Open in CIViC

This study identified genetic driver mutations by sequencing 111 genes and cytogenetic studies in 1540 samples across three different clinical trials. The prognostic significance of FLT3 tyrosine kina… (full text at CIViC)

PMID 27276561 · Papaemmanuil et al., 2016 · Open in CIViC

The study screened for mutations in the second tyrosine kinase domain of FLT3 (TK2) in 172 untreated patient with de novo AML. Nonisotopic RNase cleavage assay was used to identify samples that did no… (full text at CIViC)

PMID 15625552 · Matsuno et al., 2005 · Open in CIViC

This study identified genetic driver mutations by sequencing 111 genes and cytogenetic studies in 1540 samples across three different clinical trials. The prognostic significance of FLT3 tyrosine kina… (full text at CIViC)

PMID 27276561 · Papaemmanuil et al., 2016 · Open in CIViC

In some cancers such as infant ALL, B-lineage ALL and AML samples with the highest levels of wild-type FLT3, constitutive FLT3 phosphorylation is seen from paracrine or autocrine activation from FLT3 … (full text at CIViC)

PMID 28077790 · Nguyen et al., 2017 · Open in CIViC

46-year-old woman with normal karyotype AML; negative for ITD mutation by PCR-based FLT3 testing. Based on negative FLT3-ITD: Treated with phase 1B standard cytarabine and daunorubicin (7+3) induction… (full text at CIViC)

PMID 33914060 · Young et al., 2021 · Open in CIViC

46-year-old woman with normal karyotype AML; negative for ITD mutation by PCR-based FLT3 testing. Based on negative FLT3-ITD: Treated with phase 1B standard cytarabine and daunorubicin (7+3) induction… (full text at CIViC)

PMID 33914060 · Young et al., 2021 · Open in CIViC

The construct supported IL-3 independent growth of Ba/F3 cells. It showed FLT-3 autophosphorylation and downstream signaling via STAT5, AKT, and ERK1/2 pathways. With IL-3 deprivation, the cells showe… (full text at CIViC)

PMID 33914060 · Young et al., 2021 · Open in CIViC

In AML patients, FLT3-TKD mutation was associated with poorer disease free survival compared to patients with wild type FLT3.

PMID 17940205 · Whitman et al., 2008 · Open in CIViC

Event-free survival was significantly improved in patients with both NPM1 and FLT3-TKD mutations compared to patients with 1) FLT3-TKD mutations alone 2) either NPM1 or FLT3-TKD when FLT3-ITD patients… (full text at CIViC)

PMID 17965322 · Bacher et al., 2008 · Open in CIViC

In an in vitro study, MOLM-14, PL21 and MV4-11 cell lines expressing FLT3 internal tandem duplication mutation (FLT3-ITD) demonstrated increased sensitivity to palbociclib treatment, compared to THP-1… (full text at CIViC)

PMID 27099147 · Uras et al., 2016 · Open in CIViC

In a retrospective study of 15 acute myeloid leukemia patients, the patients with FLT3 internal tandem duplication mutation (n=2) were associated with improved response to sunitinib treatment. The pat… (full text at CIViC)

PMID 15459012 · Fiedler et al., 2005 · Open in CIViC

The FLT3 V592G variant was found in a patient with AML. BaF3 cells transformed to express V592G demonstrated proliferation in the absence of IL-3 similar to D835Y positive control. Cell proliferation … (full text at CIViC)

PMID 18068628 · Fröhling et al., 2007 · Open in CIViC

Longitudinal study analyzing blood samples over time for CHIP. The V592I was found with a VAF 0.53% (below normal CHIP threshold) in a control individual who did not develop AML.

PMID 31004019 · Young et al., 2019 · Open in CIViC